MedTrace Logo

Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation

NCT00522639 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-06-30

No results posted yet for this study

Summary

The objective of the study is to investigate the evolution ofn 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with lung cancer of during and after concurrent radiotherapy and chemotherapy

Conditions

Interventions

OTHER

18F-deoxyglucose (FDG)

contrast medium

Sponsors & Collaborators

  • Academisch Ziekenhuis Maastricht

    collaborator OTHER

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Dirk De Ruysscher, MD PhD · MAASTRO, Maastricht Radiation Oncology

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Completion
2009-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00522639 on ClinicalTrials.gov